|

Heart Disease Clinical Trials in Mississippi

31 recruiting studies across 13 cities

All Trials in Mississippi

Phase
Trial Phase Location
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)Phase 2/3Brookhaven
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityPhase 3Columbus
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityPhase 3Diamondhead
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products—Hattiesburg
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)Phase 2Jackson
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePhase 3Jackson
Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPhase 3Jackson
Cord Clamping Among Neonates With Congenital Heart DiseaseN/AJackson
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart FailureN/AJackson
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment—Jackson
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina IIN/AJackson
Encore PFO Closure Device - The PerFOrm TrialN/AJackson
IVUS CHIP UPP Registry—Jackson
Jackson Heart Study Women's Hypertension StudyN/AJackson
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease—Jackson
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular EventsPhase 3Jackson
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)—Jackson
Product Surveillance Registry—Jackson
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias—Jackson
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitablePhase 3Jackson
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionPhase 3Jackson
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity—Jackson
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionPhase 4Southaven
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)—Tupelo
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsPhase 3Tupelo
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial FibrillationPhase 2Tupelo
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACSPhase 3Tupelo
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery LesionsN/ATupelo
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small VesselsN/ATupelo
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)Phase 3Tupelo
Virtue® SAB in the Treatment of Coronary ISR TrialN/ATupelo

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.